Trade Report: Today: US Bancorp DE invests in Core Laboratories NV (CLB) Shares

Today: US Bancorp DE invests in Core Laboratories NV (CLB) Shares

US Bancorp DE raised its position in shares of Core Laboratories NV (NYSE:CLB) by 2.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 133,795 shares of the company’s stock after buying an additional 2,856 shares during the period. US Bancorp DE’s holdings in Core Laboratories NV were worth $15,030,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP increased its position in Core Laboratories NV by 61.3% in the first quarter. Wellington Management Group LLP now owns 71,480 shares of the company’s stock worth $8,035,000 after buying an additional 27,162 shares during the period. AMP Capital Investors Ltd boosted its stake in Core Laboratories NV by 47.1% in the first quarter. AMP Capital Investors Ltd now owns 19,665 shares of the company’s stock worth $2,248,000 after buying an additional 6,300 shares in the last quarter. First Republic Investment Management Inc. boosted its stake in Core Laboratories NV by 26.7% in the first quarter. First Republic Investment Management Inc. now owns 17,774 shares of the company’s stock worth $1,998,000 after buying an additional 3,750 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Core Laboratories NV by 9.1% in the second quarter. BNP Paribas Arbitrage SA now owns 5,320 shares of the company’s stock worth $659,000 after buying an additional 442 shares in the last quarter. Finally, Howland Capital Management LLC boosted its stake in Core Laboratories NV by 0.4% in the second quarter. Howland Capital Management LLC now owns 104,429 shares of the company’s stock worth $12,938,000 after buying an additional 374 shares in the last quarter.

Core Laboratories NV (NYSE:CLB) traded down 0.774% during midday trading on Monday, hitting $108.395. The stock had a trading volume of 118,844 shares. The company has a 50-day moving average price of $105.82 and a 200-day moving average price of $114.55. The company has a market cap of $4.78 billion, a price-to-earnings ratio of 73.438 and a beta of 1.40. Core Laboratories NV has a 12-month low of $84.50 and a 12-month high of $135.49.

Core Laboratories NV (NYSE:CLB) last issued its quarterly earnings results on Wednesday, October 19th. The company reported $0.38 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.38. Core Laboratories NV had a return on equity of 108.46% and a net margin of 10.17%. The business earned $143.50 million during the quarter, compared to the consensus estimate of $155.72 million. During the same period in the previous year, the business earned $0.83 EPS. The business’s quarterly revenue was down 27.3% on a year-over-year basis. Equities analysts anticipate that Core Laboratories NV will post $1.52 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, November 22nd. Stockholders of record on Friday, October 21st were issued a $0.55 dividend. The ex-dividend date of this dividend was Wednesday, October 19th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.01%. Core Laboratories NV’s dividend payout ratio (DPR) is 149.66%.

A number of analysts have recently weighed in on CLB shares. Zacks Investment Research upgraded shares of Core Laboratories NV from a “sell” rating to a “hold” rating in a report on Thursday, October 6th. Citigroup Inc. lowered their target price on shares of Core Laboratories NV from $118.00 to $116.00 and set a “neutral” rating for the company in a research note on Monday, September 12th. Credit Suisse Group AG started coverage on shares of Core Laboratories NV in a research note on Thursday, September 1st. They issued a “neutral” rating and a $115.00 target price for the company. Cowen and Company reiterated a “market perform” rating and issued a $105.00 target price on shares of Core Laboratories NV in a research note on Saturday, October 22nd. Finally, Loop Capital started coverage on shares of Core Laboratories NV in a research note on Friday, September 30th. They issued a “hold” rating and a $120.00 target price for the company. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $121.50.

Core Laboratories NV Company Profile

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

Related posts

Leave a Comment